[Adverse effects of oncohaematological immunotherapy: implications for Primary Care and continuity of care]

Antineoplastic treatment is increasingly being used due to the boom in immunotherapy, which translates into a constant change in the paradigm of the tumour approach. Immunotherapy in some tumours is a first line therapy and has drastically changed the prognosis of many of them. It has some very specific adverse effects, arising from the inhibition of the mechanisms of control of the immune response. The spectrum of toxicities is complex, and very different from that of conventional chemotherapy. This implies that these must be known by the various professionals of the different levels of care that can potentially provide care to cancer patients. A multidisciplinary and coordinated approach is required to enable them to be diagnosed and treated early, representing a clear example of the essential continuity of care, in which Primary Care plays a key role.